The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19 - 17/09/24
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Background |
Upregulation of IL-6 has been associated with worse prognosis in COVID-19 patients. Impact on IL-6 signalling has mostly been limited to clinical outcomes in IL-6 receptor antagonist trials.
Methods |
We performed a phase 2, randomised, double-blind, placebo-controlled trial (NCT04380961) of US-based hospitalised adults (<85 years) with laboratory-confirmed SARS-CoV-2 infection and severe (low levels of supplemental oxygen) or critical disease (high levels of oxygen supplementation). Patients received sirukumab 5 mg/kg or placebo single dose IV on Day 1 plus standard of care. The primary endpoint was time to sustained clinical improvement up to Day 28 based on an ordinal scale. Secondary endpoints included clinical improvement, all-cause mortality, and safety. Following an interim analysis, the protocol was amended to only recruit patients with critical COVID-19.
Findings |
From May 2020 to March 2021, 209 patients were randomised; 112 had critical disease (72 sirukumab, 40 placebo) at baseline. Median time to sustained clinical improvement in critical patients was 17 and 23 days in the sirukumab and placebo groups (HR, 1∙1; 95% CI, 0∙66–1∙88; p > 0∙05). At Day 28, 59∙4% versus 55∙0% of patients achieved clinical improvement with sirukumab versus placebo and rates of all-cause mortality were 24∙6% versus 30∙0%, respectively. Rates of grade ≥3 adverse events were comparable between the sirukumab and placebo groups (25∙9% vs 32∙9%; all patients).
Interpretation |
In critical COVID-19 patients who received sirukumab, there was no statistically significant difference in time to sustained clinical improvement versus placebo despite objective sequestration of circulating IL-6, questioning IL-6 as a key therapeutic target in COVID-19.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Adults with severe or critical COVID-19 were randomised to sirukumab or placebo. |
• | Sequestration of IL-6 upstream of the IL-6R allows testing of the IL-6 hypothesis. |
• | Sirukumab sequestered circulating IL-6 available for cis and trans signalling. |
• | Time to sustained clinical improvement was not significantly different by group. |
• | 24.6% vs 30.0% of critically ill patients died with sirukumab vs placebo. |
Keywords : COVID-19, IL-6, Sirukumab
Plan
Vol 89 - N° 4
Article 106241- octobre 2024 Retour au numéro
Article précédent
- Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study
- Mie Agermose Gram, Emilia Myrup Thiesson, Nicklas Pihlström, Jori Perälä, Eero Poukka, Tuija Leino, Rickard Ljung, Niklas Worm Andersson, Anders Hviid
- Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19 pandemic was not associated with significant serotype changes
- Catarina Silva-Costa, Joana Gomes-Silva, Marcos Pinho, Ana Friães, Fábio Subtil-Limpo, Mário Ramirez, José Melo-Cristino, on behalf of the Portuguese Group for the Study of Streptococcal Infections and the Portuguese Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society
Bienvenue sur EM-consulte, la référence des professionnels de santé.